Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 57Neoplasm Metastasis 3Stage II Prostate Adenocarcinoma 1Small Cell Lung Carcinoma 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Prostate Cancer With ≤10 Bone Metastases 1Prostate Cancer Metastatic Disease 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1Patient Preference 1Neoplasms 1Neoadjuvant Therapy 1Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Low Risk Prostate Cancer 1High-Risk and Oligometastatic Prostate Cancer 1High Risk Prostate Cancer 1Hematologic Neoplasms 1Genital Diseases, Male 1Castration Levels of Testosterone 1Carcinoma, Small Cell 1Bulbo-Spinal Atrophy, X-Linked 1Advanced Prostate Carcinoma 1

Interventions

apalutamide 1Radiotherapy 1Glutamyl Aminopeptidase 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) × apalutamide × Clear all
NCT05649943 2025-09-03

APPROACH

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase NA Recruiting
566 enrolled
Genitourinary

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡